Delayed
Warsaw S.E.
06:34:01 2024-04-29 am EDT
|
5-day change
|
1st Jan Change
|
906
PLN
|
+0.22%
|
|
+0.55%
|
-2.05%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,590
|
2,856
|
3,695
|
2,827
|
4,038
|
-
|
-
|
Enterprise Value (EV)
1 |
1,966
|
3,155
|
3,934
|
2,827
|
4,316
|
4,208
|
4,051
|
P/E ratio
|
15.4
x
|
20.4
x
|
-
|
-
|
-
|
-
|
-
|
Yield
|
1.96%
|
1.54%
|
1.37%
|
-
|
1.66%
|
2.21%
|
2.71%
|
Capitalization / Revenue
|
0.19
x
|
0.31
x
|
0.37
x
|
0.25
x
|
0.31
x
|
0.3
x
|
0.28
x
|
EV / Revenue
|
0.24
x
|
0.34
x
|
0.4
x
|
0.25
x
|
0.33
x
|
0.31
x
|
0.28
x
|
EV / EBITDA
|
9.24
x
|
11.3
x
|
14.2
x
|
8.33
x
|
9.9
x
|
8.47
x
|
7.22
x
|
EV / FCF
|
24.3
x
|
13.2
x
|
15.9
x
|
-
|
24
x
|
18.4
x
|
15.1
x
|
FCF Yield
|
4.12%
|
7.59%
|
6.29%
|
-
|
4.16%
|
5.44%
|
6.62%
|
Price to Book
|
2.47
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
4,207
|
4,387
|
4,399
|
4,350
|
4,467
|
-
|
-
|
Reference price
2 |
378.0
|
651.0
|
840.0
|
650.0
|
904.0
|
904.0
|
904.0
|
Announcement Date
|
3/18/20
|
3/25/21
|
3/30/22
|
3/28/23
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
8,279
|
9,254
|
9,864
|
11,233
|
12,984
|
13,687
|
14,294
|
EBITDA
1 |
212.8
|
279.1
|
277.7
|
339.2
|
436
|
496.5
|
561
|
EBIT
1 |
157.2
|
214.5
|
198.2
|
241.3
|
317.5
|
368
|
412.5
|
Operating Margin
|
1.9%
|
2.32%
|
2.01%
|
2.15%
|
2.45%
|
2.69%
|
2.89%
|
Earnings before Tax (EBT)
1 |
155
|
194
|
-
|
202
|
281
|
346.5
|
415.5
|
Net income
1 |
117.7
|
143.7
|
150.7
|
136.4
|
177.5
|
230
|
264
|
Net margin
|
1.42%
|
1.55%
|
1.53%
|
1.21%
|
1.37%
|
1.68%
|
1.85%
|
EPS
|
24.59
|
31.94
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
80.95
|
239.5
|
247.4
|
-
|
179.5
|
229
|
268
|
FCF margin
|
0.98%
|
2.59%
|
2.51%
|
-
|
1.38%
|
1.67%
|
1.87%
|
FCF Conversion (EBITDA)
|
38.04%
|
85.82%
|
89.1%
|
-
|
41.17%
|
46.12%
|
47.77%
|
FCF Conversion (Net income)
|
68.8%
|
166.68%
|
164.25%
|
-
|
101.13%
|
99.57%
|
101.52%
|
Dividend per Share
2 |
7.400
|
10.00
|
11.50
|
-
|
15.00
|
20.00
|
24.50
|
Announcement Date
|
3/18/20
|
3/25/21
|
3/30/22
|
3/28/23
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q2
|
2023 Q3
|
2024 Q1
|
---|
Net sales
1 |
2,552
|
2,681
|
-
|
2,655
|
2,809
|
2,891
|
-
|
3,196
|
EBITDA
1 |
78.7
|
60.06
|
-
|
96.6
|
76.7
|
85.3
|
-
|
110.6
|
EBIT
1 |
58.9
|
38.01
|
-
|
73.6
|
52.8
|
57.7
|
-
|
79.7
|
Operating Margin
|
2.31%
|
1.42%
|
-
|
2.77%
|
1.88%
|
2%
|
-
|
2.49%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
40.1
|
-
|
59.74
|
-
|
-
|
21
|
45.08
|
51.3
|
Net margin
|
1.57%
|
-
|
-
|
-
|
-
|
0.73%
|
-
|
1.61%
|
EPS
|
8.620
|
-
|
13.01
|
-
|
-
|
-
|
9.990
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/21
|
3/30/22
|
5/18/22
|
8/30/22
|
11/16/22
|
8/29/23
|
11/14/23
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
375
|
299
|
238
|
-
|
278
|
169
|
12.7
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.764
x
|
1.072
x
|
0.8581
x
|
-
|
0.6376
x
|
0.341
x
|
0.0225
x
|
Free Cash Flow
1 |
80.9
|
240
|
247
|
-
|
180
|
229
|
268
|
ROE (net income / shareholders' equity)
|
18.4%
|
21.9%
|
18.2%
|
-
|
16.7%
|
18.4%
|
18.9%
|
ROA (Net income/ Total Assets)
|
3.55%
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
3,314
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
153.0
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
121
|
85.2
|
52.8
|
-
|
145
|
152
|
165
|
Capex / Sales
|
1.47%
|
0.92%
|
0.53%
|
-
|
1.11%
|
1.11%
|
1.15%
|
Announcement Date
|
3/18/20
|
3/25/21
|
3/30/22
|
3/28/23
|
-
|
-
|
-
|
Average target price
974.7
PLN Spread / Average Target +7.82% Consensus |
1st Jan change
|
Capi.
|
---|
| -2.05% | 998M | | +17.35% | 71.39B | | +2.39% | 25.1B | | -1.22% | 8.59B | | +6.69% | 8.19B | | -20.96% | 7.91B | | -0.12% | 4.54B | | +17.12% | 4.31B | | -2.61% | 3.86B | | +22.08% | 3.64B |
Pharmaceuticals Wholesale
|